n-acetyllactosamine has been researched along with Ascites in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhat, NM; Bieber, MM; Chen, Y; Teng, NNH | 1 |
| Carrasco, J; Courtoy, PJ; Demotte, N; Lurquin, C; Moser, M; Schmidt, C; Squifflet, JL; Thielemans, K; van der Bruggen, P; Van Der Smissen, P; Weynand, B; Wieërs, G | 1 |
2 other study(ies) available for n-acetyllactosamine and Ascites
| Article | Year |
|---|---|
Ovarian carcinoma glyco-antigen targeted by human IgM antibody.
Topics: Amino Sugars; Antibodies, Monoclonal; Antigens, Neoplasm; Ascites; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Immunoglobulin M; Microscopy, Electron, Scanning; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2017 |
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.
Topics: Amino Sugars; Animals; Ascites; Breast Neoplasms; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Galectin 3; Humans; Interferon-gamma; Ligands; Lymphocytes, Tumor-Infiltrating; Mastocytoma; Melanoma; Mice; Neoplasms; Pleural Effusion, Malignant; Polysaccharides; Receptors, Antigen, T-Cell | 2010 |